We found that POG exhibited the best antitumour effect at a dose of 100 mg/kg and reduced the proportion of PMN-MDSCs in the bone marrow, spleen and CD45+ cells in tumours (Fig. 3f–h). This evidence concerns the gene PTPRC and neoplasm.